Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +51.68%
#2 TENDIES TENDIES +51.33%
#3 Pons Pons +46.31%
#4 PondCoin PondCoin +45.60%
#5 StonkBroker StonkBroker +34.96%
#6 Magma Finance Magma Finance +32.98%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +27.14%
#8 Starpower Starpower +26.90%
#9 Purr Purr +26.74%
#10 Ocean Protocol Ocean Protocol +26.36%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Resverlogix Corp. Resverlogix Corp.

Resverlogix Corp.

RVX
Clasificación en acciones #28673
Resverlogix Corporation is a biotechnology firm currently in advanced clinical... Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Precio por acción
$0.07339369
Última sincronización: 2026-08-18
Capitalización bursátil
$25.24M
Cambio (1 día)
5.26%
Cambio (1 año)
-9.55%
País
CA
Comercio Resverlogix Corp. (RVX)

Categoría

Healthcare
Ganancias de Resverlogix Corp. (RVX)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Resverlogix Corp., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Resverlogix Corp. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH